Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELO-SCOPE danazol trial in pulmonary fibrosis with short telomeres
ACTRN12620001363976Phase 2Terminated
- Sponsor
- The University of Queensland
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary fibrosis (PF) and Fibrosing interstitial pneumonia (FIP) comparing Danazol + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in telomere length at 12 months. Started Sep 2021; status: terminated.
02
Drugs
danazol
03
Conditions
pulmonary fibrosis (PF)Fibrosing interstitial pneumonia (FIP)
Beyond the preview
Go deeper on ACTRN12620001363976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001363976.